Ligand id: 6787

Name: alefacept

No information available.
Summary of Clinical Use
This drug was approved for the treatment of inflammation in moderate to severe psoriasis with plaque formation. Use of alefacept has since been discontinued in the US.
Mechanism Of Action and Pharmacodynamic Effects
When alefacept binds to CD2 on the surface of T cells, it prevents the CD2/LFA3 interaction required to generate the co-stimulatory signal which would activate the T cells. This action inhibits the activation of CD4+ and CD8+ T cells resulting an immunosuppressive effect which results in reduced proliferation of keratinocytes, hyperproliferation of which cause psoriatic plaque formation [2].